According to the contract between Farzan Clinical Research and Clintec International, Farzan Clinical Research would manage the Iranian sites for a study on infertility sponsored by Merck Serono. This is a phase IIIB interventional multicenter and multinational study. Royan Institute, one of the most famous research centers in Iran, would recruit the patients. Iranian Ministry of Health and Medical Education – FDA has also approved the study. FDA National Ethics Committee and Royan Institutional Ethics Committee have also approved the study.
Farzan Clinical Research is the first Iranian Clinical Research Organization (CRO). Farzan Clinical Research is now an important partner for many Universities, research centers, scientific societies as well as pharmaceutical and medical device industry. After 10 years experience in providing medical research services as Farzan Institute for Science, Research & Technology, Farzan Clinical Research was founded in Feb 2008 as the first Iranian registered CRO and now offers Clinical Trial Management, Clinical Trial Monitoring, Data Management, Biostatistics and Medical Writing services. Farzan Clinical Research is certified by Ministry of Health and Medical Education- Food and Drug Organization (FDA) – Islamic Republic of Iran. The Best National Entrepreneur prize was awarded to Farzan Clinical Research and Farzan was acknowledged by President of Islamic Republic of Iran in July 2011.
Clintec International is a privately owned medium sized CRO with a global reach and a strong presence in the emerging markets of Asia Pacific, Middle East & Africa and Eastern & Central Europe. With flexible resourcing services across 80 countries, ClinTec provides clinical research personnel and support services to the pharmaceutical, biotechnology and medical device industry.
Merck Serono is a pharmaceutical company headquartered in Geneva, Switzerland. In addition to internal research and development activities Merck Serono is also involved in publicly funded collaborative research projects, with other industrial and academic partners. Merck Serono is the Largest division of Merck KgaA, Established in January 5, 2007 as a Biopharmaceutical company. The number of Employees is about 17000 and the Total revenue of Merck Serono was € 5.9 billion in 2011. The major therapeutic areas are Oncology, Neurodegenerative Diseases, Fertility, Endocrinology, CardioMetabolic Care & General Medicine. The products of Merck Serono is commercialized in 150 countries.
